ReviewCurrent psychiatry reports2010
Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.
Review in Current psychiatry reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- ADHD Prescription Medications and Their Effect on Athletic Performance: A Systematic Review and Meta-analysis.Sports medicine - open · 2022Pooled it
- Exploring the Effects of Pharmacological, Psychosocial, and Alternative/Complementary Interventions in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Meta-Regression Approach.The international journal of neuropsychopharmacology · 2021Pooled it
- Comparative Study of the Adverse Events Associated With Adjuvant Use of Dexmedetomidine and Clonidine in Local Anesthesia.Frontiers in medicine · 2021Pooled it
- ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Genetic mapping identifies Homer1 as a developmental modifier of attention.Nature neuroscience · 2026Article
- Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy.Biomedicines · 2025Review
- Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice Experiment.Patient preference and adherence · 2024Article
- The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review.Neurology international · 2023Review
- Common practical questions - and answers - at the British Association for Psychopharmacology child and adolescent psychopharmacology course.Journal of psychopharmacology (Oxford, England) · 2023Review
- Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia.NPJ Parkinson's disease · 2022Article
- Fragile X Syndrome: From Molecular Aspect to Clinical Treatment.International journal of molecular sciences · 2022Review
- Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials.Frontiers in pharmacology · 2022Review
- Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.Frontiers in human neuroscience · 2022Review
- Impact of holding home stimulant(s) on agitation in a child and adolescent inpatient psychiatric population.The mental health clinician · 2021Article
- Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder.Antioxidants (Basel, Switzerland) · 2020Review
- Antioxidants as a Potential Target against Inflammation and Oxidative Stress in Attention-Deficit/Hyperactivity Disorder.Antioxidants (Basel, Switzerland) · 2020Review
- The use of reaction time distributions to study attention in male rats: the effects of atomoxetine and guanfacine.Psychopharmacology · 2019Article
- The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder.Psychiatry investigation · 2018Article
- Article
- Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder.Neuropsychiatric disease and treatment · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Pharmacologic management of attention-deficit/hyperactivity disorder (ADHD) has expanded beyond stimulant medications to include alpha-2 adrenergic agonists. These agents exert their actions through presynaptic stimulation and likely involve facilitation of dopamine and noradrenaline neurotransmission, both of which are thought to play critical roles in the pathophysiology of ADHD. Furthermore, frontostriatal dysfunction giving rise to neuropsychological weaknesses has been well-established in patients with ADHD and may explain how alpha-2 agents exert their beneficial effects. In the following review, we consider relevant neurobiological underpinnings of ADHD with respect to why alpha-2 agents may be effective in treating this condition. We also review new formulations of alpha-2 agonists, emerging data on their use in ADHD, and implications for clinical practice. Integrating knowledge of pathophysiologic mechanisms and mechanisms of drug action may inform our medication choices and facilitate treatment of ADHD and related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.